Table 3.

Assessments of primary and secondary end points.

	Pitavastatin n = 54 (%)	Control n = 54 (%)	p
DIND	7 (13.0)	12 (22.2)	0.16
Angiographic vasospasm			0.03
None or mild	28 (51.9)	20 (37.0)
Moderate	18 (33.3)	16 (29.6)
Severe	8 (14.8)	18 (33.3)
Cerebral infarction	6 (11.1)	13 (24.1)	0.12
Poor outcome	8 (14.8)	10 (18.5)	0.39

DIND: delayed neurological ischemic deficits.